Which genetic alteration is noted as AML-ETO?

The correct genetic alteration noted as AML-ETO is the translocation t(8;21). This specific translocation is typically associated with acute myeloid leukemia (AML) and results in the fusion of the AML1 gene (also known as RUNX1) on chromosome 21 and the ETO gene (also known as RUNX1T1) on chromosome 8. This fusion gene plays a significant role in the pathogenesis of this subtype of AML by disrupting normal hematopoiesis and promoting leukemogenesis.

In contrast, the other options refer to different genetic alterations associated with other types of leukemias or distinct transformations. For instance, the translocation t(15;17) is characteristic of acute promyelocytic leukemia (APL), related to the fusion of the promyelocytic leukemia (PML) gene and the retinoic acid receptor alpha (RARA) gene. The t(16;16) translocation is commonly associated with acute myeloid leukemia with abnormal eosinophils, leading to a specific type of AML labeled as acute myeloid leukemia with inv(16). The inversion inv(16), also linked to acute myeloid leukemia, involves a rearrangement of chromosome 16